%0 Journal Article
%@ 1743-7075
%A Karusheva, Yanislava
%A Kunstein, Lejla
%A Bierwagen, Alessandra
%A Nowotny, Bettina
%A Kabisch, Stefan
%A Groener, Jan B.
%A Fleitmann, Ann Kristin
%A Herder, Christian
%A Pacini, Giovanni
%A Strassburger, Klaus
%A Häring, Hans-Ulrich
%A Nawroth, Peter P.
%A Pfeiffer, Andreas F. H.
%A Burkart, Volker
%A Müssig, Karsten
%A Roden, Michael
%A Szendroedi, Julia
%C London
%D 2018
%F heidok:25805
%I BioMed Central
%J Nutrition & Metabolism
%N 90
%P 1-8
%T An 8-week diet high in cereal fiber and coffee but free of red meat does not improve beta-cell function in patients with type 2 diabetes mellitus: a randomized controlled trial
%U https://archiv.ub.uni-heidelberg.de/volltextserver/25805/
%V 15
%X Background: Higher dietary intake of fibers and coffee, but lower red meat intake is associated with reduced risk for type 2 diabetes in epidemiological studies. We hypothesized that a calorie-restricted diet, which is high in fiber and coffee, but free of red meat, improves beta-cell function in patients with T2D.       Methods: In a randomized parallel-group pilot trial, obese type 2 diabetes patients were randomly allocated to consume either a diet high in cereal fiber and coffee, but free of red meat (n = 17) (L-RISK) or a diet low in fiber, free of coffee but high in red meat (n = 20) (H-RISK) for 8 weeks. Insulin secretion was assessed from glucagon stimulation tests (GST) and mixed-meal tolerance tests (MMTT) before and after dietary intervention.     Results: Both diets resulted in comparable reduction of fasting concentrations of insulin (H-RISK -28% vs. L-RISK -32%, both p < 0.01), C-peptide (H-RISK -26% vs. L-RISK -30%, both p < 0.01) and blood glucose (H-RISK -6.8%, p < 0.05 vs. L-RISK -10%, p < 0.01). Gastric inhibitory peptide (GIP) secretion increased by 24% after 8 weeks in the L-RISK only (p < 0.01). However, GST and MMTT showed no differences in insulin secretion after intervention.    Conclusions: Calorie restriction independent of the intake of fiber, coffee or meat failed to improve beta-cell function, but improved GIP secretion in obese patients with type 2 diabetes.      Trial registration: Registration at Clinicaltrials.gov, Identifier number: NCT01409330  , Registered 4 August 2011 – Retrospectively registered.